MS cuts rating on Enfusion stock after Clearwater’s acquisition bid
Investing.com -- Morgan Stanley downgraded Enfusion Inc (NYSE:ENFN) stock to "Equal-weight" from "Overweight" following Clearwater Analytics' proposed $1.5 billion acquisition at $11.25 per share.With the bid accelerating value realization, Morgan Stanley (NYSE:MS) raised its price target by 25 cents to $11.25, in line with the offer price.